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Background: Chronic kidney disease is an important public health threat. Such patients present high morbidity
and mortality due to cardiovascular disease, with low quality of life and survival, and also high expenditure resulting
from the treatment. Arterial hypertension is both a cause and a complication of kidney disease; also, arterial
hypertension is a risk factor for cardiovascular disease among patients with kidney diseases. There is some evidence
that exercise interventions may be beneficial to chronic kidney disease patients, but previous studies included only
end-stage patients, i.e. those undergoing dialysis. This study aims to evaluate the effect of exercise on kidney
function, quality of life and other risk factors for cardiovascular disease among non-diabetic chronic hypertensive
kidney disease patients who are not undergoing dialysis.
Methods: The participants will be located through screening hypertensive patients attended within the public
healthcare network in Pelotas, a city in south of Brazil. Eligible individuals will be those with glomerular filtration
rate between 15 and 59 ml/min x 1.73 m2. The randomization will be done in fixed-size blocks of six individuals
such that 75 participants will be allocated to each group. At baseline, information on demographic, socioeconomic,
behavioral, anthropometric, blood pressure and quality-of-life variables will be collected, and laboratory tests will be
performed. The intervention will consist of three weekly physical exercise sessions lasting 60–75 minutes each, with
a total duration of 16 weeks. The outcomes will be the kidney function progression rate, quality of life, blood
pressure, lipid profile, hemoglobin level, ultrasensitive C-reactive protein level, and ankle-arm index. The patients in
both groups (intervention and control) will be reassessed and compared partway through the study (8th week), at
the end of the intervention (16th week) and in the 8th week after the end of the intervention.
Discussion: There is still a scarcity of data relating to the effect of physical exercise among the most numerous
group of individuals with kidney disease, i.e. patients undergoing conservative treatment. In particular, there is a
lack of randomized controlled studies. This study will help fill this gap.Background
Chronic kidney disease is an important public health
threat [1]. Studies in several countries have estimated that
around 12% of the population presents kidney dysfunction
(glomerular filtration rate < 60 ml/min x 1.73 m2) and that
this rate becomes greater with increasing age [2-4].
Patients with chronic kidney disease present high morbid-
ity and mortality due to cardiovascular diseases (DCV)
[5], with low quality of life and survival [6].* Correspondence: franklin.sul@terra.com.br
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frequently as a result of diabetes mellitus or systemic ar-
terial hypertension. Systemic arterial hypertension is both
a cause and a complication of chronic kidney disease and
hypertension is a risk factor for cardiovascular diseases
among these patients [7]. Kidney disease patients who are
not undergoing dialysis have been studied less often than
those receiving dialysis. Strategies are required for keeping
these patients’ kidneys functioning and attenuating the
risk factors for cardiovascular diseases. Physical inactivity
may be an important determinant of morbidity and mor-
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ciated with lower cardiovascular risk [9]. Individuals of all
ages and both sexes benefit from moderate-intensity phys-
ical activity, with diminished risk of cardiovascular dis-
eases, maintenance of muscle strength, maintenance of
the ability to remain independent, reduction of the risk of
falling, fewer symptoms of depression and anxiety and
improved quality of life, with increased psychological and
physical wellbeing [10]. Physical activity is inversely asso-
ciated with rates of kidney dysfunction among diabetic
patients [11,12]. Despite this evidence, patients with
chronic kidney disease tend to be inactive [13]. Moreover,
most experimental studies have only included in the inter-
vention group the healthier portion of the patients indi-
cated for kidney replacement therapy, thus making it
difficult to extrapolate the results to the whole population
undergoing dialysis.
Data on the effect of physical exercise among the most
numerous group of individuals with chronic kidney dis-
eases, i.e. patients at less advanced stages of the disease
who are still receiving conservative treatment, are still
scarce [13]. Furthermore, most studies that have dealt
with this influence on chronic renal disease patients were
conducted in high-income countries, involving small sam-
ples, with short intervention periods, and few were rando-
mized and controlled. There is therefore a need for good-
quality data regarding the impact of physical exercise on
the prognosis for patients with chronic kidney diseases,
and especially in relation to the large group of individuals
with kidney diseases in its earliest stages. In addition to
the cardiovascular and quality-of-life benefits from inter-
ventions, this group also presents the characteristic of po-
tential delay in the progression of nephropathy, which is a
benefit that can no longer be expected among the group
indicated for kidney replacement therapy. Also, there is an
urgent need to reduce the burden of cardiovascular events
and the numbers of individuals with indications for dialy-
sis among this population.
Objectives and main measurements
The aim of the present study is to evaluate the effect of
an exercise program on non-diabetic hypertensive
patients with chronic kidney disease with regard to dis-
ease progression and quality of life. The hypothesis is
that patients with chronic kidney disease who perform
physical exercises (intervention group) will present less
deterioration of kidney function and an increase in the
quality-of-life score. Quality of life will be measured by
means of the Medical Outcomes Study 36-Item Short
Form Health Survey (SF-36), using the Portuguese ver-
sion translated and validated by Ciconelli [14].
Additionally, the efficacy of the physical exercise will
also be assessed by comparing the intervention and con-
trol groups regarding the following variables: (a) bloodpressure and the need to use antihypertensive medica-
tions; (b) serum levels of total cholesterol, HDL choles-
terol, triglycerides, albumin, ultrasensitive C-reactive
protein, hemoglobin and hematocrit; (c) excretion of
proteins and creatinine in urine; (d) ankle-arm index;
Methods
Design and setting
A randomized controlled trial will be conducted among
patients with chronic kidney disease. The study will be
supervised within the Postgraduate Program in Epidemi-
ology in conjunction with the School of Physical Educa-
tion of the Federal University of Pelotas, which is located
in the city of Pelotas, in the south of Brazil. The sample
will be composed of non-diabetic individuals presenting
systemic arterial hypertension with a glomerular filtration
rate of between 15 and 59 ml/min x 1.73 m2 (therefore
characterized as being in stages 3 or 4 of chronic kidney
disease [1]), who are attending primary health care units
in the urban zone of the city.
Recruitment and eligibility
The records of the “HiperDia” project, held by the City
Health Department, contain the numbers of individuals
with systemic arterial hypertension registered at each
primary health care unit in the municipality [15]. After
obtaining the names of these patients, their medical files
at the primary health care units will be reviewed. Non-
diabetic patients with diagnoses of systemic arterial
hypertension who in 2009 presented serum creatinine
levels greater than or equal to 1.0 mg/dl and glomerular
filtration rates (as calculated using the Diet in Renal Dis-
ease four variables assessment formula) [16] between 15
and 59 ml/min x 1.73 m2 will be identified.
Exclusion criteria
The following patients will be excluded from the study:
a) Diabetics – we opted to exclude patients with
diabetes because they present different prognosis as
compared to chronic kidney disease patients without
diabetes [17];
b) Individuals with severe physical disabilities (stroke
sequelae, lower-limb amputation without a
prosthesis, and orthopedic diseases that worsen with
exercise);
c) Individuals with a history of acute myocardial
infarction over the last six months;
d) Individuals with kidney transplants or who are
undergoing dialysis treatment.
Sample size calculation
Due to the lack of baseline population-based Brazilian
data on kidney function, we carried out a pilot study in
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primary health care units in the city of Pelotas in 2010
in order to obtain the estimates needed for the sample
size calculation. Through reviewing 3800 medical files,
290 patients with glomerular filtration rates of less than
60 ml/min x 1.73 m2 were identified. In this subsample,
the glomerular filtration rate of non-diabetic hyperten-
sive patients in stages 3 and 4 of chronic kidney disease
was 48.47 ± 9.61 ml/min x 1.73 m2. To identify a post-
intervention difference greater than or equal to 10% be-
tween the intervention and control groups that is signifi-
cant at the 5% level (two-tailed), with a power of 80% at
the end of 16 weeks, it will be necessary to include 63
patients in each group of the study. We decided to ex-
pand the sample to 75 patients per group in order to
take follow-up losses into account based on previous
trials with chronic kidney disease patients. This sample
size also allows detecting baseline vs. post-intervention
differences of 10% or greater in both groups.
Random allocation
Random allocation will be performed after the indivi-
duals who agreed to participate have been interviewed
and have undergone a physical examination. The alloca-
tion list will be concealed and patients will be allocated
to either the intervention or the control group. In order
to balance the groups in terms of numbers of partici-
pants, we will use the technique of randomization in
fixed-size blocks of six individuals. For each group of six
individuals, we will make a draw for the order of entry
in each group (intervention or control).
The individuals identified from the “HiperDia” records
will be visited at home and invited to participate in the
study. After recruitment, a baseline study will be con-
ducted to assess the individuals of both groups before
the intervention. The main variables to be collected will
be: demographic and socioeconomic data (sex, age,
socioeconomic level, schooling level, skin color and
marital status); behavioral characteristics (physical activ-
ity, smoking and alcohol consumption); anthropometric
data (weight, height and waist circumference); clinical
data (length of time with diagnosis of hypertension,
blood pressure in the upper and lower limbs and anti-
hypertensive medications currently used); venous blood
and urine sample collection for laboratory analyses
(hemogram, lipid profile, blood glucose, serum albumin,
ultrasensitive C-reactive protein, proteinuria and creati-
ninuria); and quality of life. The blood and urine samples
will be collected at home following an overnight fast
(~12 hours) by a nursing technician, and will be sent to
the support laboratory, packed in refrigerated boxes at a
temperature of approximately 4 °C. Interviewers will be
blinded to the interventions or control status of each
patient.These patients will be interviewed again at home part-
way through the study (in the 8th week), just after the
end of the intervention (16th week) and in the 8th week
after the end of the intervention (Figure 1). At these
three visits, a short version of the baseline questionnaire
will be applied, and the anthropometric and blood pres-
sure measurements and laboratory tests will be redone.
Again, interviewers will be blinded for the intervention
or control status of each patient. All the laboratory tests
will be performed in a single laboratory, in order to en-
sure comparability. The questionnaires and the physical
examinations will be applied to the participants by previ-
ously trained medical students and resident physicians
within clinical medical at the School of Medicine of the
Catholic University of Pelotas, under supervision by the
study coordinator. In all the evaluations, 10 % of the
subjects will receive a telephone call from the fieldwork
supervisor for quality control purposes.
Intervention and procedures
The intervention will consist of 16 weeks of physical ex-
ercise sessions lasting for an average of 60–75 minutes,
at a frequency of three sessions per week. One of the
basic principles of exercise training is the progression of
intensity, duration or frequency [18]. In our interven-
tion, the progression will be based on two main vari-
ables: (a) increases in the effort-rest ratio; (b) reduction
in the cool-down time of the sessions, with an increase
in the main part of the classes. The workout intensity
will be controlled by means of Borg’s Perceived Exertion
Scale applied for Resistance Exercise [19].
All patients from the intervention group will be submit-
ted to an acclimation period, in which light and moderate-
intensity activities will be prioritized. The intervention will
comprise aerobic activities, resistance training and muscle
power training. The workout sessions will be composed of
an initial section of 5 to 10 minutes of body warm-up and
stretching exercises, a main section of circuit or interval
training [19-21] with aerobic and resistance exercises last-
ing for 30 to 35 minutes, and 10–15 minutes of core mus-
cles endurance and flexibility. The final part of the class
will be composed of stretching and relaxation exercises
lasting approximately 10 minutes.
Resistance training from weeks 1–10 will comprise
multi-joint exercises (squat, curved row, bench press,
upright row and biceps curl plus shoulder extension),
and from weeks 11–16, we will also include low-
intensity plyometric training. In terms of muscle power
training, we will conduct 2–3 repetitions of 4–6 simple
horizontal jumps in the first 14 weeks. In the last two
weeks, vertical jumps will also be included [22].
The control group will continue to receive the usual
attendance provided by the primary health care unit, in
accordance with the guidelines of the Ministry of
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Figure 1 Description of the study protocol.
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tion of cardiovascular, cerebrovascular and chronic kid-
ney diseases [23]. The control group patients will answer
the same questionnaires and will undergo all the phys-
ical examinations and laboratory tests at the baseline, in
the 8th and 16th weeks after the start of the intervention
and in the 8th week after the end of the intervention,
similarly to what will be done with patients from the
intervention group.Follow-up and adherence to the study
Since the aim of the study is to assess the efficacy of the
intervention, strategies for ensuring follow-ups with
complete adherence will be used. At the start of the
study, the participants will be informed about the im-
portance of the follow-up, and the names, addresses and
telephone numbers of two individuals who are close to
the participant and who might be able to inform where
the participant can be found will be recorded. Over the
course of the study, the participants in the intervention
group will be contacted by telephone on the day preced-
ing the physical activity sessions. Participants will be
offered a snack at the end of each intervention session,
transportation vouchers for them to come to the ses-
sions and a pair of training shoes and sports clothes to
use at the physical exercise sessions. Participants who do
not come to one of the sessions will be sought in their
homes to find out why they had been absent. If neces-
sary to ensure adherence, the study will provide door-to-
door transportation, free of charge for participants. The
intervention will take place between August 2011 and
July 2012. The sessions will be administered by physical
education professionals, through an agreement with the
School of Physical Education of the Federal University of
Pelotas, within the premises of the school.Primary and secondary outcomes
Progression of kidney disease will be assessed according
to glomerular filtration rate measurements, estimated
from the four variables formula for Modification of Diet
in Renal Disease (MDRD). The glomerular filtration rate
will be estimated in the intervention and control groups
from serum creatinine measurements obtained at the
baseline, in the 8th and 16th weeks after the start of the
intervention and in the 8th week after the end of the inter-
vention. Protein excretion in urine will be evaluated
through the proteinuria ratio in milligrams per deciliter
(mg/dl) and the creatininuria ratio (mg/dl), taking the
index to be normal when it is less than 0.3. A secondary
outcome is quality of life, which will be measured using
the Medical Outcomes Study Short Form 36 item (SF-36).
It comprises eight scales, each scored from 0 to 100.Measurements
Blood pressure: for measurements of systolic and dia-
stolic blood pressure, the mean from two measurements
made five minutes apart, with the patient seated, will be
used. In order to maintain precision, an automatic de-
vice for blood pressure measurement will be used
(Omron HEM-705-CP), and the adult cuff size will be
selected (the cuff width should be 40% of the brachial
circumference and its length should be 80%). The
patients will remain seated, with the arm supported at
heart level. They will remain at rest for five minutes be-
fore the measurement and should not have had coffee or
smoked within the preceding 30 minutes.
Medications: to measure the consumption of medica-
tions, the questionnaire standardized by Bertoldi and
colleagues [24] will be used. The numbers and names of
medications used by the participants will be recorded.
Blood and urine samples: will be collected after the
participants have been under fasting conditions for
12 hours. Assays to determine serum levels of total chol-
esterol, HDL cholesterol, triglycerides, blood glucose,
ultrasensitive C-reactive protein, hemoglobin and
hematocrit will be performed. Protein and creatinine
concentrations will be measured in urine samples. Pro-
teinuria will be assayed using the colorimetric method,
with pyrogallol red in a photometric device. Plasma and
urinary creatinine will be analyzed by means of kinetics,
Jaffe’s method with distilled water and using Roche re-
agent. Total cholesterol and HDL cholesterol will be
measured by means of a colorimetric cholesterol esterase
enzymatic method.
Ankle-arm index: this index will be measured with
the patient in dorsal decubitus, as the mean of two
systolic pressure measurements on the dominant bra-
chial artery (right arm for right-handed individuals
and left arm for left-handed individuals), to obtain
the proximal pressure; and on the posterior tibial of
the ipsilateral leg to obtain the distal pressure [25].
These measurements will be made, respectively, by
means of a sphygmomanometer and the Microem
DV10 portable vascular Doppler ultrasound equip-
ment (ANVISA/MS registration no. 10301810012).
The index is then obtained as the ratio between the
distal and proximal pressures.
In addition to these variables, physical activity before
and after the intervention will be quantified. Physical ac-
tivity practice during leisure time and as a means of
transport will be evaluated using the long version of the
International Physical Activity Questionnaire (IPAQ)
[26]. This outcome will assess the sustainability of the
intervention in the intervention group, eight weeks after
the end of the programmed exercise sessions, in com-
parison with the level of physical activity in the control
group at the same point in time.
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At the baseline, in addition to data on sociodemographic,
behavioral and anthropometric characteristics, length of
time with the diagnosis of hypertension and laboratory
parameters, information on the following factors will be
gathered:
1. Medications:
a) Use of antihypertensive agents that block the
angiotensin system (angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers) that
may be associated with diminished progression of
kidney disease;
b)Use of non-steroidal anti-inflammatory drugs, which,
on the contrary, may increase the progression of
chronic kidney disease.
c) Level of physical activity before the start of the study.
Quality control
The day-to-day progress of the study will be closely
monitored by the coordinator, who will be available to
resolve any queries that may arise over the course of the
fieldwork. The physical exercise sessions of the interven-
tion group will be monitored by a research assistant,
who will record the names of those who are present,
identify those who are absent and organize home visits
within the next 24 hours after the session for the partici-
pants who did not attend. According to the reason for
the absence, appropriate measures will be taken in order
to ensure maximum adherence to the study among the
participants.
Data colleting and analysis
Data will be double-entered into the Epi-Info software in
order to make subsequent comparison and thus ensure
greater data quality. Automatic data checking will be
performed, at the time of data entry, using the check
function of Epi-Info, in order to verify range and
consistency. To identify and correct inconsistencies of
coding, revision and data entry, data cleaning will be
performed by obtaining the frequencies of the variables
gathered, using the Stata 11.0 software. This software
will also be used for the data analysis. A two-tailed sig-
nificance level of 5 % will be used for all the analyses.
The two groups will firstly be compared in terms of the
frequencies of the independent variables (demographic,
socioeconomic and behavioral factors and time since ar-
terial hypertension was diagnosed), blood pressure
levels, glomerular filtration rates and other dependent
variables. All analyses will be conducted using intention
to treat, i.e., each individual will be analyzed in the
group to which he or she was initially allocated, inde-
pendent of dropouts from the intervention group or any
beginning of physical activity among members of thecontrol group. Outcome variables (glomerular filtration
rate and quality of life) will be compared in the two
groups using T-test. We will use confidence intervals for
estimating treatment effects.
Ethical issues
The research ethics committee of the Federal University
of Pelotas has approved this study. Likewise, the study
has been authorized by the City Health Department and
by the coordinators of the health care clinics involved in
this study. The results from this study will be communi-
cated to the Health Department of Pelotas and to the
Regional Healthcare Coordination Office. Interviewees
will be asked to give their written informed consent to
their inclusion and will be assured of the right not to an-
swer any part or the whole questionnaire, and their right
to withdraw from the study at any time, without any
onus on the participant or his/her family.
After the end of the study, if any benefits relating to
the disease are found, we will offer the same activity
under the same conditions to all participants in the
study.
Competing interests
The authors declare there are no financial competing interests to declare in
relation to this manuscript.
Authors’ contributions
FCB made substantial contributions to conception and design of the study.
PH conceived the study, and participated in its design and coordination and
helped to draft the manuscript. IS involved in drafting the manuscript and
revising it critically for important intellectual content. GM participated in the
design of the study. FBV is in charge of the exercise intervention. All authors
read and approved the final manuscript.
Author details
1Postgraduate Program in Epidemiology, Federal University of Pelotas, Brazil,
Rua Marechal Deodoro, 1160, Pelotas, RS, Brazil. 2Postgraduate Program in
Physical Education, Federal University of Pelotas, Brazil, Rua Luiz de Camões,
625, Pelotas, RS, Brazil.
Received: 1 July 2011 Accepted: 31 July 2012
Published: 28 August 2012
References
1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al:
Definition and classification of chronic kidney disease: a position
statement from Kidney Disease: Improving Global Outcomes (KDIGO).
Kidney Int 2005, 67:2089–100.
2. Coresh J, Selvin E, Stevens LA, et al: Prevalence of chronic kidney disease
in the United States. JAMA 2007, 298:2038–2047.
3. Chadban SJ, Briganti EM, Kerr PG, et al: Prevalence of kidney damage in
Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2003,
14:131–138.
4. Imai E, Matsuo S: Chronic kidney disease in Asia. Lancet 2008,
371:2147–2148.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE:
Clinical and echocardiographic disease in patients starting end-stage
renal disease therapy. Kidney Int 1995, 47:186–92.
6. Codreanu I, Perico N, Sharma SK, Schieppati A, Remuzzi G: Prevention
programmes of progressive renal disease in developing nations.
Nephrology 2006, 11:321–8.
7. Mayer G: An update on the relationship between the kidney, salt and
hypertension. Wien Med Wochenschr 2008, 158:365–9.
Barcellos et al. BMC Nephrology 2012, 13:90 Page 7 of 7
http://www.biomedcentral.com/1471-2369/13/908. Word Heath Organization. Diet, nutrition and the preventions of chronic
diseases: Report of a Joint WHO/FAO Expert Consultation. WHO Technical
report Series: Report of a Joint WHO/FAO Expert Consultation; 2003.
9. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS: Physical activity and
the incidence of coronary heart disease. Annu Rev Public Health 1987,
8:253–87.
10. Kosmadakis GC, Bevington A, Smith AC, Clapp EL, Viana JL, Bishop NC, et al:
Physical exercise in patients with severe kidney disease. Nephron Clin
Pract 2010, 115:c7–c16.
11. Kriska AM, LaPorte RE, Patrick SL, Kuller LH, Orchard TJ: The association of
physical activity and diabetic complications in individuals with insulin-
dependent diabetes mellitus: the Epidemiology of Diabetes
Complications Study–VII. J Clin Epidemiol 1991, 44:1207–14.
12. Krop JS, Saudek CD, Weller WE, Powe NR, Shaffer T, Anderson GF:
Predicting expenditures for Medicare beneficiaries with diabetes.
A prospective cohort study from 1994 to 1996. Diabetes Care 1999,
22:1660–6.
13. Johansen K, Painter P: Exercise for patients with CKD: what more is
needed? Adv Chronic Kidney Dis 2009, 16:407–9.
14. Ciconelli RM, Soarez PC, Kowalski CC, Ferraz MB: The Brazilian Portuguese
version of the Work Productivity and Activity Impairment: General
Health (WPAI-GH) Questionnaire. Sao Paulo Med J 2006, 124:325–32.
15. BRASIL: Ministério da Saúde. Secretaria de Políticas de Saúde, Departamento
de Ações Programáticas Estratégicas. Brasília: Ministério da Saúde: Plano de
reorganização da atenção à hipertensão arterial e ao diabetes mellitus;
2001.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130:461–70.
17. Greenberg A, Cheung AK: National Kidney Foundation. 5th ed. San Diego:
Academic Press: Primer on kidney diseases; 2009.
18. Baechle T, Earle R: Essentials of Strength Training and Conditioning 3rd Edition.
Champaign: Human Kinetics; 2008.
19. Row BS, Knutzen KM, Skogsberg NJ: Regulating explosive resistance
training intensity using the rating of perceived exertion. J Strength Cond
Res 2012, 26(3):664–671.
20. WisLo FF, Ellingsen U, Kemi O: High-intensity interval training to maximize
cardiac benefits of exercise training? Exerc. Sport Sci. Rev 2009,
37(3):139–146.
21. Chtara M, Chaouachi A, Levin GT, Chaouachi M, Chamari K, Amri M, Laursen PB:
Effect of concurrent endurance and circuit resistance-training sequence on
muscular strength and power development. J Strength Cond Res 2008,
22:1037–1045.
22. Shiner J, Bishop T, Cosgarea AJ: Integrating low-intensity plyometrics into
strength and conditioning programs. Strength and Conditioning Journal
2005, 27(6):10–20.
23. BRASIL: Ministério da Saúde. Brasília: Ministério da Saúde: Manual de
Condutas Médicas: hipertensão arterial e diabetes mellitus; 2002.
24. Bertoldi AD, Barros AJ, Hallal PC: Generic drugs in Brazil: known to many,
used by few. Cadernos de Saúde Pública (ENSP. Impresso) 2005,
21(6):1808–1815.
25. Newman AB, Siscovick DS, Manolio TA, et al: Ankle-arm index as a marker
of atherosclerosis in the Cardiovascular Health Study. Circulation 1993,
88:837–845.
26. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE,
Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P: International physical activity
questionnaire: 12-country reliability and validity. Med Sci Sports Exerc
2003, 35:1381–95.
doi:10.1186/1471-2369-13-90
Cite this article as: Barcellos et al.: Effects of exercise on kidney function
among non-diabetic patients with hypertension and renal disease:
randomized controlled trial. BMC Nephrology 2012 13:90.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
